Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR mHealth and uHealth

Date Submitted: Sep 27, 2020
Date Accepted: Jul 15, 2021

The final, peer-reviewed published version of this preprint can be found here:

Effect of Physician-Pharmacist Participation in the Management of Ambulatory Cancer Pain Through a Digital Health Platform: Randomized Controlled Trial

Zhang L, McLeod HL, Liu KK, Liu WH, Huang HX, Huang YM, Sun SS, Chen XP, Chen Y, Liu FZ, Xiao J

Effect of Physician-Pharmacist Participation in the Management of Ambulatory Cancer Pain Through a Digital Health Platform: Randomized Controlled Trial

JMIR Mhealth Uhealth 2021;9(8):e24555

DOI: 10.2196/24555

PMID: 34398796

PMCID: 8406114

Effect of physician-pharmacist participation in the management of ambulatory cancer pain through a digital health platform: A randomized controlled trial

  • Lu Zhang; 
  • Howard L McLeod; 
  • Ke-Ke Liu; 
  • Wen-Hui Liu; 
  • Hang-Xing Huang; 
  • Ya-Min Huang; 
  • Shu-Sen Sun; 
  • Xiao-Ping Chen; 
  • Yao Chen; 
  • Fang-Zhou Liu; 
  • Jian Xiao

ABSTRACT

Background:

Management of ambulatory cancer pain is a difficult clinical challenge, with opportunities to individualize patient care.

Objective:

We conducted a randomized controlled trial to assess the impact of physician-pharmacist participation in self-management of ambulatory cancer pain by using the WeChat-supported platform—Medication Housekeeper (MediHK).

Methods:

Patients were randomly assigned to either an intervention group (InterG) or control group (CTLG). During the four weeks study period, the participants in InterG completed daily 24-hour pain diaries, adverse reaction (ADR) forms every 3 days and the Brief Pain Inventory (BPI) every 15 days from pharmacists via MediHK, while the participants in CTLG only received conventional pharmaceutical care and any information they proactively requested. The primary outcome included pain intensity and pain interference on daily life. Secondary outcomes included Patient Reported Outcome Measures (PROMs), adherence, adverse reaction (ADRs) and rehospitalization rate.

Results:

A total of 100 patients were included, with 51 in the InterG and 49 in the CTLG. The worst pain scores, the least pain scores and the average pain scores in the InterG and the CTLG were statistically different, with a median value of 4.0 (IQR, 3.0-7.0) vs. 7.0 (IQR, 4.5-8.0) (P = 0.001), 1.0 (0-2.0) vs. 2.0 (IQR, 1.0-3.0) (P = 0.017), 2.0 (2.0-4.0) vs. 4.0 (IQR, 3.0-5.0) (P = 0.001) at the end of the study. Except for walking ability and normal work, pain interference on all areas showed greater reductions in InterG. The total adherence rate increased from 94.1% to 100.0% in the InterG group and 77.6% to 83.7% in CTLG. The overall number of ADRs increased at the four week and more ADRs were monitored in the InterG (P=0.003). Rehospitalization rate was similar between the two groups.

Conclusions:

With the help of MediHK, the joined Intervention of physicians and pharmacists optimized outcomes and promoted self-management of patients in home settings. This study supports the feasibility of integrating the internet into self-management of cancer pain patients.


 Citation

Please cite as:

Zhang L, McLeod HL, Liu KK, Liu WH, Huang HX, Huang YM, Sun SS, Chen XP, Chen Y, Liu FZ, Xiao J

Effect of Physician-Pharmacist Participation in the Management of Ambulatory Cancer Pain Through a Digital Health Platform: Randomized Controlled Trial

JMIR Mhealth Uhealth 2021;9(8):e24555

DOI: 10.2196/24555

PMID: 34398796

PMCID: 8406114

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.